首页 › 基金 › Kohlberg Kravis Roberts & Co. L.P. › BBIO
Kohlberg Kravis Roberts & Co. L.P. 对 BBIO 的持仓历史
BRIDGEBIO PHARMA INC · 医疗保健
Kohlberg Kravis Roberts & Co. L.P. 在 Q3 2026 的 13F 申报中披露持有 BBIO(BRIDGEBIO PHARMA INC)385,000 股,市值约 US$581K,约占其申报组合的 0.01%,在其申报持仓中市值排名第 45 位。 Kohlberg Kravis Roberts & Co. L.P. 最近 13 个申报季度中有 13 个季度披露了 BBIO 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Kohlberg Kravis Roberts & Co. L.P. 对 BBIO 的持仓演变
Kohlberg Kravis Roberts & Co. L.P. 于 Q3 2023 首次披露 BBIO 持仓:31,060,971 股(约 US$819.1M)。 该持仓在 Q4 2023 达到峰值 31,060,971 股,市值约 US$1.25B。 在 13 次申报中,Kohlberg Kravis Roberts & Co. L.P. 0 次增持、4 次减持、8 次保持不变。 最近一期申报(Q3 2026)显示持股 385,000 股、市值约 US$581K。 持仓曾出现大幅变动:Q2 2025 减持约 31% (随后一个季度股价上涨 20%)、Q2 2026 减持约 97% (随后一个季度股价下跌 12%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 31.06M | $819.08M | 新进 |
| Q4 2023 | 31.06M | $1.25B | 持有 |
| Q1 2024 | 31.06M | $960.41M | 持有 |
| Q2 2024 | 31.06M | $786.77M | 持有 |
| Q3 2024 | 25.26M | $643.14M | 减持 |
| Q4 2024 | 25.26M | $693.16M | 持有 |
| Q1 2025 | 19.26M | $665.85M | 减持 |
| Q2 2025 | 13.26M | $572.61M | 减持 |
| Q3 2025 | 13.26M | $688.77M | 持有 |
| Q4 2025 | 13.26M | $1.01B | 持有 |
| Q1 2026 | 13.26M | $984.76M | 持有 |
| Q2 2026 | 385.00K | $648.53K | 减持 |
| Q3 2026 | 385.00K | $580.77K | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 BBIO 与 13F 数据
BBIO(BRIDGEBIO PHARMA INC)属于医疗保健行业。我们追踪的基金中还有 41 只申报持有 BBIO,申报仓位最大的包括:Jupiter Topco LLC (US$1.05B), 骏利亨德森集团 (US$978.6M), 法拉龙资本管理 (US$800.1M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 BBIO 的基金
- Jupiter Topco LLC 14.11M 股 · $1.05B · Q2 2026
- 骏利亨德森集团 13.18M 股 · $978.61M · Q1 2026
- 法拉龙资本管理 10.74M 股 · $800.14M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.74M 股 · $800.14M · Q2 2026
- 维京环球投资 9.95M 股 · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M 股 · $741.02M · Q2 2026
- Aisling Capital Management LP 3.09M 股 · $203.30M · Q3 2026
- SC US (TTGP), LTD. 1.86M 股 · $138.56M · Q2 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 69.87M 股 · $124.49M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.55M 股 · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M 股 · $102.27M · Q2 2026
- Hood River Capital Management LLC 1.35M 股 · $100.36M · Q2 2026
更多关于 Kohlberg Kravis Roberts & Co. L.P.
常见问题
How long has Kohlberg Kravis Roberts & Co. L.P. held BBIO?
Kohlberg Kravis Roberts & Co. L.P. has disclosed BBIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Kohlberg Kravis Roberts & Co. L.P.'s current position in BBIO?
As of Q3 2026, Kohlberg Kravis Roberts & Co. L.P. holds 385.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $580.77K, representing 0.01% of its reported portfolio and ranking #45.
Has Kohlberg Kravis Roberts & Co. L.P. been buying or selling BBIO?
In the latest 13F filing (Q3 2026), Kohlberg Kravis Roberts & Co. L.P. held unchanged its position in BBIO. The position peaked in Q4 2023 at 31.06M shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, 骏利亨德森集团, 法拉龙资本管理, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.